Characteristic | 16–25 | 26–35 | 36–45 | 46–55 | All |
---|---|---|---|---|---|
N = 862 | N = 1098 | N = 2189 | N = 4121 | N = 8270 | |
% of age group with AKI | 39.8 | 46.6 | 52.5 | 58.5 | 52.6 |
Age (years), Median (Q1–Q3) | 22 (19–24) | 31 (28–33) | 41 (39–44) | 51 (48–53) | 45 (36–51) |
Males N (%) | 573 (66.5) | 670 (61.2) | 1304 (60) | 2500 (61) | 5047 (61) |
Race N (%) | |||||
White | 597 (69) | 790 (72) | 1654 (76) | 3127 (76) | 6168 (76) |
Black | 132 (15) | 131 (12) | 226 (10) | 409 (10) | 898 (11) |
Other | 133 (15) | 177 (16) | 309 (14) | 585 (14) | 1204 (15) |
Reference creatinine (mg/dl), median (Q1–Q3) | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) |
eGFR (ml/min/1.73 m2), median (Q1–Q3) | 121.2 (92.8–133) | 111.4 (81.9–123.1) | 95.7 (79.4–113.9) | 86.2 (76.9–104.8) | 96.5 (78.6–113.2) |
Fluid balance > 5% | 111 (12.9) | 161 (14.7) | 285 (13.1) | 485 (11.8) | 1042 (12.6) |
Cardiac disease N (%) | 41 (5) | 95 (9) | 225 (10) | 666 (16) | 1027 (12) |
Chronic kidney disease N (%) | 16 (2) | 26 (2) | 135 (6) | 218 (5) | 395 (5) |
Diabetes N (%) | 50 (6) | 102 (9) | 227 (10) | 741 (18) | 1120 (14) |
History of hypertension N (%) | 59 (7) | 135 (12) | 459 (21) | 1274 (31) | 1927 (23) |
Malignancy N (%) | 7 (0.8) | 15 (1) | 62 (2.8) | 156 (3.8) | 240 (3) |
Multiple comorbidities N (%) | 142 (17) | 290 (26) | 803 (37) | 1889 (46) | 3124 (38) |
Mechanical ventilation N (%) | 580 (67) | 684 (62) | 1340 (61) | 2413 (59) | 5017 (61) |
Surgical admission N (%) | 504 (65) | 601 (60) | 1128 (57) | 2216 (59) | 4449 (59) |
Suspected sepsis N (%) | 122 (14) | 198 (18) | 395 (18) | 698 (17) | 1413 (17) |
APACHE III score, median (Q1–Q3) | 54 (36–72) | 53 (34–73) | 52 (35–74) | 57 (38–80) | 55 (37–76) |
Vasopressor use N (%) | 149 (17) | 224 (20) | 521 (24) | 1125 (27) | 2019 (24) |
Moderate anemia N (%) | 227 (26) | 315 (29) | 577 (26) | 1259 (31) | 2378 (29) |
Maximum KDIGO N (%) | |||||
Stage 1 | 400 (46) | 444 (41) | 738 (34) | 1241 (30) | 2823 (34) |
Stage 2 | 335 (39) | 433 (39) | 906 (41) | 1783 (43) | 3457 (42) |
Stage 3 | 127 (15) | 221 (20) | 545 (25) | 1097 (27) | 1990 (24) |
Medication exposure N (%) | |||||
ACE inhibitor/ARB | 21(2) | 27 (2) | 93 (4) | 269 (7) | 410 (5) |
Vancomycin | 124 (14) | 203 (18) | 373 (17) | 669 (16) | 1369 (17) |
Aminoglycoside | 31 (3.6) | 44 (4) | 87 (4) | 157 (4) | 319 (4) |
Other Antibiotics | 62 (7) | 82 (7) | 137 (6) | 258 (6) | 539 (6) |
Calcineurin inhibitor | 58 (7) | 94 (9) | 153 (7) | 264 (6) | 569 (7) |
NSAID | 40 (5) | 90 (8) | 269 (12) | 716 (17) | 1115 (14) |
Acyclovir | 18 (2) | 29 (2.6) | 462 (2.1) | 67 (1.6) | 160 (2) |
Mannitol | 28 (3) | 26 (2) | 32 (1.5) | 30 (0.7) | 116 (1) |
Phenytoin | 32 (3.7) | 24 (2) | 47 (2) | 82 (2) | 185 (2) |